The Baveno Cooperation: an EASL Consortium
LightNews LightNews
banner
bavenocoop.bsky.social
The Baveno Cooperation: an EASL Consortium
@bavenocoop.bsky.social
220 followers 46 following 52 posts
The official account of the Baveno Cooperation
Posts Replies Media Videos
bavenocoop.bsky.social
🚨Just 3 weeks away‼️
Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷

🗓️ Dec 4–5 @ CNAM
💳 Onsite €150 | 💻 Online FREE
👉 Organized by EURO-VALDIG NET & FILFOIE
🔗 Registration → app.evalandgo.com/f/325218/4qE...
📘 Updated program below 👇
#LiverTwitter
November 13, 2025 at 8:29 AM
Reposted by The Baveno Cooperation: an EASL Consortium
martatejedor4.bsky.social
And if you look after adult patients with #MASLD, here is a cue on how to approach treatment 👇

#TLM25 #LiverSky
November 8, 2025 at 11:09 AM
Reposted by The Baveno Cooperation: an EASL Consortium
martatejedor4.bsky.social
How to approach #MASLD at different stages of our patients lives

Fantastic summary slide from @marurinella

#PostGraduateCourse #TLM25 @aasldnews.bsky.social
November 8, 2025 at 11:09 AM
Reposted by The Baveno Cooperation: an EASL Consortium
martatejedor4.bsky.social
So excited to be in Washington DC for my first #TLM25 with wonderful colleagues!

A toast to you all with a delicious mocktail! Will see you around! Can’t wait!

#LiverTwitter @aasldnews.bsky.social
November 8, 2025 at 11:11 AM
Reposted by The Baveno Cooperation: an EASL Consortium
atoosarabiee.bsky.social
Recompensation take home points

⏳off all diuretics and medications for HE
📌happens in 1 out of 3 patients depending etiology
🖋️multiple factors affect it
🔎 improves survival and LR mortality
📍Risk of HCC remains the same: don’t stop screening

@anahitarabiee.bsky.social
#liversky
#TLM25
November 8, 2025 at 1:50 PM
Reposted by The Baveno Cooperation: an EASL Consortium
atoosarabiee.bsky.social
Best practices of management of obesity in liver transplant

FANTASTIC work by @drjessicadavis.bsky.social et al leading a controversy conference and consensus paper 👇🏼👇🏼👇🏼

Her beautiful graph won the cover photo 👌🏼

#liversky
#TLM25
@aasldnews.bsky.social
@ast-licop.bsky.social
November 9, 2025 at 4:09 PM
bavenocoop.bsky.social
🎬 Want to know why you should register for the VALDIG PSVD Meeting 2025 in Paris 🇫🇷?

🗓️ Dec 4–5 @ CNAM
💳 Onsite €150 | 💻 Online FREE

Watch the video below and see why you can’t miss it!
🔗 Register here: app.evalandgo.com/f/325218/4qE...
November 6, 2025 at 12:09 PM
bavenocoop.bsky.social
🚨Just one month away‼️
Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷

🗓️ Dec 4–5 @ CNAM
💳 Onsite €150 | 💻 Online FREE
👉 Organized by EURO-VALDIG NET & FILFOIE
🔗 Registration -> app.evalandgo.com/f/325218/4qE...
📘 Full program below 👇 #LiverTwitter
November 5, 2025 at 4:03 PM
Reposted by The Baveno Cooperation: an EASL Consortium
atoosarabiee.bsky.social
In anticipation of registration for @bavenocoop.bsky.social VIII

Do not miss this new publication on
refining Baveno VII criteria for CSPH
individual-patient data meta-analysis

#liversky
pubmed.ncbi.nlm.nih.gov/41138818/
@easlnews.bsky.social
October 27, 2025 at 5:18 PM
Reposted by The Baveno Cooperation: an EASL Consortium
reibergerthomas.bsky.social
Loss of Bile Salt Export Pump (Bsep/Abcb11) Ameliorates Toxin-induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-terminal Kinase Signaling and Hepatic Stellate Cell Activation -

Cellular and Molecular Gastroenterology and Hepatology
www.cmghjournal.org/article/S235...
Loss of Bile Salt Export Pump (Bsep/Abcb11) Ameliorates Toxin-induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-terminal Kinase Signaling and Hepatic Stellate Cell Activation
Loss of Bsep/Abcb11 results in a hydrophilic bile acid (BA) pool consisting of tetrahydroxylated BAs (THBAs) reducing cholestasis-induced liver injury. In this study, we investigated whether loss of B...
www.cmghjournal.org
October 27, 2025 at 8:29 PM
bavenocoop.bsky.social
⏳ Just 5 months left for #BavenoVIII!
🗓️ 27-28 March 2026 (👶 Pediatric Symposium: 29 March)
📍 Baveno, Italy
🌐 The event will take place in a hybrid formula — both in person and online.
🧠 Call for abstracts is now open!
🔗 More info at: baveno8.org
🧵
October 27, 2025 at 1:45 PM
Reposted by The Baveno Cooperation: an EASL Consortium
reibergerthomas.bsky.social
#Liver #Cirrhosis #PortalHypertension
A recent @meduniwien.ac.at study investigated #cirrhosis pts with variceal bleeding over two 🕐 🕕 🕘 decades:
✅ decreasing rebleeding🩸rates
✅ lower bleeding-related ☠️ mortality
in the more recent decade ☺️

📕 GIE Endoscopy
🔗 www.giejournal.org/article/S001...
Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades
Acute variceal bleeding (AVB), a severe adverse event of portal hypertension, may cause death in patients with cirrhosis. We investigated whether outcomes after AVB have improved over time.
www.giejournal.org
October 15, 2025 at 9:19 PM
bavenocoop.bsky.social
🔬 Passionate about vascular liver diseases?
Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷!

🗓️ Dec 4–5 @ CNAM
💳 Onsite €150 | 💻 Online free
👉 Organized by EURO-VALDIG NET & FILFOIE

Register here ➡️ app.evalandgo.com/f/325218/4qE...

Full program 👇
October 15, 2025 at 5:30 AM
Reposted by The Baveno Cooperation: an EASL Consortium
mattiasmandorfer.bsky.social
Overview on published/presented data on MASH cirrhosis #LiverSky @bavenocoop.bsky.social

🖇️: authors.elsevier.com/sd/article/S...
October 3, 2025 at 7:06 AM
bavenocoop.bsky.social
🚨 Join us for the VALDIG PSVD Meeting – a 2-day event dedicated to PSVD!

🗓️ Dec 4–5, 2025
📍 CNAM, Paris 🇫🇷
💳 Onsite €150 (payment after reg.) | Online free
👉Organized by EURO-VALDIG NET & FILFOIE

Register here ➡️ app.evalandgo.com/f/325218/4qE...

Program 👇
October 1, 2025 at 11:49 AM
Reposted by The Baveno Cooperation: an EASL Consortium
aga-cgh.bsky.social
🔎Around 1 in 4 people with CCA have chronic liver diseases, and 1 in 10 have cirrhosis.
Read more here: ❇️ ow.ly/GIh450X2qc0
September 26, 2025 at 5:36 PM
Reposted by The Baveno Cooperation: an EASL Consortium
reibergerthomas.bsky.social
Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
September 28, 2025 at 7:14 PM
Reposted by The Baveno Cooperation: an EASL Consortium
nejm.org
In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results and Research Summary: nej.md/4p6tIDo
The New England Journal of Medicine Apixaban for Extended Treatment of Provoked Venous Thromboembolism A Research Summary based on Piazza G et al. | 10.1056/NEJMoa2509426 | Published on August 30, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
September 29, 2025 at 1:01 PM
Reposted by The Baveno Cooperation: an EASL Consortium
natrevgastrohep.nature.com
New online! Interaction of inflammation and portal hypertension in cirrhosis progression
Interaction of inflammation and portal hypertension in cirrhosis progression
Nature Reviews Gastroenterology & Hepatology, Published online: 29 September 2025; doi:10.1038/s41575-025-01107-2Portal hypertension and systemic inflammation are key factors driving decompensation and organ failure in cirrhosis. This Review examines those two factors and, based on their mechanistic interaction, proposes a new concept of the clinical phenotypes in decompensated cirrhosis.
www.nature.com
September 29, 2025 at 12:58 PM
Reposted by The Baveno Cooperation: an EASL Consortium
atoosarabiee.bsky.social
If you are interested in portal hypertension and like to hear from all disciplines involved, this is the conference for you 👇🏼

Thank you for the invitation and the opportunity to review HRS-AKI and ascites management.

#liversky
@portal360mtg.bsky.social
@bavenocoop.bsky.social
September 26, 2025 at 4:10 PM
bavenocoop.bsky.social
🚨 Mark your calendars! Baveno VIII Meeting → 27–28 March 2026

Reminder from @crisripoll.bsky.social, Baveno Vice-Secretary at #DGVS

⏳ only 6 months left!

Register 👉 bavenocoop.net
September 19, 2025 at 3:25 PM
Reposted by The Baveno Cooperation: an EASL Consortium
mattiasmandorfer.bsky.social
@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension

👀 at our auditorium

🙏 incredible hospitality

👉 See our 🇯🇵 friends at Baveno VIII
September 12, 2025 at 9:53 AM
bavenocoop.bsky.social
The passing of Prof. Jaume Bosch (1947–2025) has generated, and continues to generate, heartfelt tributes

Here you can read some of them:

Scientific societies
🇪🇺EASL: journal-of-hepatology.eu/action/showP...
🇪🇸AEEH: aeeh.es/obituario-ja...
🇨🇭SASL: sasl.unibas.ch/files/mixed%...
September 4, 2025 at 9:32 AM
Reposted by The Baveno Cooperation: an EASL Consortium
bavenocoop.bsky.social
🔗 Full paper: doi.org/10.1111/apt....

📝 Editorial by @reibergerthomas.bsky.social and Benedikt Simbrunner:
onlinelibrary.wiley.com/doi/epdf/10....

#LiverTwitter
Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial)
There is no evidence of a difference between carvedilol 12.5 mg daily and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium-to large-sized oesophageal varices. ....
doi.org
May 9, 2025 at 3:06 PM
Reposted by The Baveno Cooperation: an EASL Consortium
sanchitsharma2188.bsky.social
Some evidence on role of Simvastatin and Carvedilol in patients after variceal🩸. Stage of cirrhosis and right combination may b the 🔑 for statins in PHTN
#LiverSky. @easlnews.bsky.social @bavenocoop.bsky.social @amcollegegastro.bsky.social @aasldnews.bsky.social

journals.lww.com/ajg/abstract...
August 6, 2025 at 12:06 AM